Form 8-K · Current report
News Corp 8-K, filed Aug 5, 2026
- Filed
- CIK
- 0001564708
- Accession no.
- 0001564708-26-000167
Summary
News Corp filed an 8-K disclosing daily buy-back activity under its 2025 Repurchase Program, which authorizes up to $1 billion in aggregate repurchases of its Nasdaq-listed Class A and Class B common stock. The company reported buying back 62,323 shares for about $1.76 million on August 4, 2026, bringing cumulative purchases under the program to roughly $404.7 million.
Key points
- The 2025 Repurchase Program, authorized July 15, 2025, permits repurchases of up to $1 billion in aggregate of News Corp's Class A and Class B common stock.
- Cumulative buy-backs under the program reached 10,288,925 shares for total consideration of about $261.96 million before August 4, 2026, plus 62,323 shares for about $1.76 million on that day.
- News Corp stated it has purchased approximately $404,733,910 worth of Class A and Class B shares under the program to date, based on total consideration paid.
- No ASX-listed CDIs will be repurchased under the program.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01 Other Events. As previously reported, under News Corporation's (the "Company's") stock repurchase program (the "Repurchase Program"), the Company is authorized to acquire from time to time up to $1 billion in the aggregate of the Company's outstanding shares of Class A common stock and Class B common stock. Under the rules of the Australian Securities Exchange (the "ASX"), the Company is required to provide to the ASX, on a daily basis, disclosure of transactions pursuant to the Repurchase Program, if any. The Company also discloses information concerning the Repurchase Program in the Company's quarterly and annual reports. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.